Cargando…

Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia

BACKGROUND: Cytokines were correlated with survival and disease progression in acute myeloid leukemia (AML). We aimed to evaluate the multivariate effect of TNF‐α rs361525, rs1800750, rs1800629, IL‐10 rs1800896, rs1800872, IL‐6 rs1800795, TGF‐β1 rs1800470, IFN‐γ rs2430561 single nucleotide polymorph...

Descripción completa

Detalles Bibliográficos
Autores principales: Bănescu, Claudia, Tripon, Florin, Trifa, Adrian P., Crauciuc, Andrei G, Moldovan, Valeriu G., Bogliş, Alina, Benedek, Istvan, Dima, Delia, Cândea, Marcela, Duicu, Carmen, Iancu, Mihaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745852/
https://www.ncbi.nlm.nih.gov/pubmed/31373163
http://dx.doi.org/10.1002/cam4.2424
_version_ 1783451605398454272
author Bănescu, Claudia
Tripon, Florin
Trifa, Adrian P.
Crauciuc, Andrei G
Moldovan, Valeriu G.
Bogliş, Alina
Benedek, Istvan
Dima, Delia
Cândea, Marcela
Duicu, Carmen
Iancu, Mihaela
author_facet Bănescu, Claudia
Tripon, Florin
Trifa, Adrian P.
Crauciuc, Andrei G
Moldovan, Valeriu G.
Bogliş, Alina
Benedek, Istvan
Dima, Delia
Cândea, Marcela
Duicu, Carmen
Iancu, Mihaela
author_sort Bănescu, Claudia
collection PubMed
description BACKGROUND: Cytokines were correlated with survival and disease progression in acute myeloid leukemia (AML). We aimed to evaluate the multivariate effect of TNF‐α rs361525, rs1800750, rs1800629, IL‐10 rs1800896, rs1800872, IL‐6 rs1800795, TGF‐β1 rs1800470, IFN‐γ rs2430561 single nucleotide polymorphisms (SNPs) on AML risk, the multivariate effect of SNPs on overall survival (OS) in AML and the association between the investigated SNPs and prognostic factors in AML. METHODS: All SNPs were genotyped in 226 adult AML cases and 406 healthy individuals. AML patients were investigated for FLT3 (ITD, D835), DNMT3A (R882), and NPM1 type A mutations. RESULTS: Univariate analysis revealed that age above 65 years had a negative influence on survival (P < .001). The presence of the rs1800750 variant genotype (P = .005) or FLT3‐ITD mutation (P = .009) in a cytogenetic high‐risk group (P = .003) negatively influenced OS. A negative association was observed between Eastern Cooperative Oncologic Group Scale status > 2, lactate dehydrogenase (LDH) level, platelet (PLT) count <40 000 cells/mm(3), and OS. Multivariate Cox regression analysis showed that the presence of the rs1800750 variant genotype was a risk factor for death (P = .007), and that blast percentage, LDH level (≥600 IU/L), and cytogenetic high‐risk were independent significant predictors for death in AML (P = .04, corrected HR = 1.20; P = .022, corrected HR = 1.24; P = .021, corrected HR = 1.34, respectively). CONCLUSIONS: Age above 65 years, PLT count, TNF‐α rs1800750 variant genotype, blast percentage, LDH level, and cytogenetic high‐risk may be used as independent risk factors to assess AML mortality.
format Online
Article
Text
id pubmed-6745852
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67458522019-09-18 Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia Bănescu, Claudia Tripon, Florin Trifa, Adrian P. Crauciuc, Andrei G Moldovan, Valeriu G. Bogliş, Alina Benedek, Istvan Dima, Delia Cândea, Marcela Duicu, Carmen Iancu, Mihaela Cancer Med Clinical Cancer Research BACKGROUND: Cytokines were correlated with survival and disease progression in acute myeloid leukemia (AML). We aimed to evaluate the multivariate effect of TNF‐α rs361525, rs1800750, rs1800629, IL‐10 rs1800896, rs1800872, IL‐6 rs1800795, TGF‐β1 rs1800470, IFN‐γ rs2430561 single nucleotide polymorphisms (SNPs) on AML risk, the multivariate effect of SNPs on overall survival (OS) in AML and the association between the investigated SNPs and prognostic factors in AML. METHODS: All SNPs were genotyped in 226 adult AML cases and 406 healthy individuals. AML patients were investigated for FLT3 (ITD, D835), DNMT3A (R882), and NPM1 type A mutations. RESULTS: Univariate analysis revealed that age above 65 years had a negative influence on survival (P < .001). The presence of the rs1800750 variant genotype (P = .005) or FLT3‐ITD mutation (P = .009) in a cytogenetic high‐risk group (P = .003) negatively influenced OS. A negative association was observed between Eastern Cooperative Oncologic Group Scale status > 2, lactate dehydrogenase (LDH) level, platelet (PLT) count <40 000 cells/mm(3), and OS. Multivariate Cox regression analysis showed that the presence of the rs1800750 variant genotype was a risk factor for death (P = .007), and that blast percentage, LDH level (≥600 IU/L), and cytogenetic high‐risk were independent significant predictors for death in AML (P = .04, corrected HR = 1.20; P = .022, corrected HR = 1.24; P = .021, corrected HR = 1.34, respectively). CONCLUSIONS: Age above 65 years, PLT count, TNF‐α rs1800750 variant genotype, blast percentage, LDH level, and cytogenetic high‐risk may be used as independent risk factors to assess AML mortality. John Wiley and Sons Inc. 2019-08-01 /pmc/articles/PMC6745852/ /pubmed/31373163 http://dx.doi.org/10.1002/cam4.2424 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Bănescu, Claudia
Tripon, Florin
Trifa, Adrian P.
Crauciuc, Andrei G
Moldovan, Valeriu G.
Bogliş, Alina
Benedek, Istvan
Dima, Delia
Cândea, Marcela
Duicu, Carmen
Iancu, Mihaela
Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia
title Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia
title_full Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia
title_fullStr Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia
title_full_unstemmed Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia
title_short Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia
title_sort cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 snps in relation with prognostic factors in acute myeloid leukemia
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745852/
https://www.ncbi.nlm.nih.gov/pubmed/31373163
http://dx.doi.org/10.1002/cam4.2424
work_keys_str_mv AT banescuclaudia cytokiners361525rs1800750rs1800629rs1800896rs1800872rs1800795rs1800470andrs2430561snpsinrelationwithprognosticfactorsinacutemyeloidleukemia
AT triponflorin cytokiners361525rs1800750rs1800629rs1800896rs1800872rs1800795rs1800470andrs2430561snpsinrelationwithprognosticfactorsinacutemyeloidleukemia
AT trifaadrianp cytokiners361525rs1800750rs1800629rs1800896rs1800872rs1800795rs1800470andrs2430561snpsinrelationwithprognosticfactorsinacutemyeloidleukemia
AT crauciucandreig cytokiners361525rs1800750rs1800629rs1800896rs1800872rs1800795rs1800470andrs2430561snpsinrelationwithprognosticfactorsinacutemyeloidleukemia
AT moldovanvaleriug cytokiners361525rs1800750rs1800629rs1800896rs1800872rs1800795rs1800470andrs2430561snpsinrelationwithprognosticfactorsinacutemyeloidleukemia
AT boglisalina cytokiners361525rs1800750rs1800629rs1800896rs1800872rs1800795rs1800470andrs2430561snpsinrelationwithprognosticfactorsinacutemyeloidleukemia
AT benedekistvan cytokiners361525rs1800750rs1800629rs1800896rs1800872rs1800795rs1800470andrs2430561snpsinrelationwithprognosticfactorsinacutemyeloidleukemia
AT dimadelia cytokiners361525rs1800750rs1800629rs1800896rs1800872rs1800795rs1800470andrs2430561snpsinrelationwithprognosticfactorsinacutemyeloidleukemia
AT candeamarcela cytokiners361525rs1800750rs1800629rs1800896rs1800872rs1800795rs1800470andrs2430561snpsinrelationwithprognosticfactorsinacutemyeloidleukemia
AT duicucarmen cytokiners361525rs1800750rs1800629rs1800896rs1800872rs1800795rs1800470andrs2430561snpsinrelationwithprognosticfactorsinacutemyeloidleukemia
AT iancumihaela cytokiners361525rs1800750rs1800629rs1800896rs1800872rs1800795rs1800470andrs2430561snpsinrelationwithprognosticfactorsinacutemyeloidleukemia